Carmat Asset Resilience Ratio
Carmat asset resilience ratio. Carmat (ALCAR) has an Asset Resilience Ratio of 39.63% as of June 2012. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALCAR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Carmat (2009–2017)
Asset resilience ratio of Carmat from 2009 to 2017. This chart shows how Carmat's Asset Resilience Ratio has changed over time. Read Carmat debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Carmat's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Carmat total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.15 Million | 39.63% |
| Total Liquid Assets | €10.15 Million | 39.63% |
Asset Resilience Insights
- Very High Liquidity: Carmat maintains exceptional liquid asset reserves at 39.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Carmat Industry Peers by Asset Resilience Ratio
Compare Carmat's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Carmat Asset Resilience Ratio by Year (2009–2017)
Carmat asset resilience ratio by year from 2009 to 2017. The table below shows the annual Asset Resilience Ratio data for Carmat.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | €0.00 ≈ $0.00 |
€69.85 Million ≈ $81.66 Million |
-- |
| 2016-12-31 | 21.36% | €8.01 Million ≈ $9.36 Million |
€37.49 Million ≈ $43.83 Million |
-28.49pp |
| 2014-12-31 | 49.85% | €7.00 Million ≈ $8.18 Million |
€14.04 Million ≈ $16.42 Million |
+23.02pp |
| 2011-12-31 | 26.83% | €10.04 Million ≈ $11.74 Million |
€37.43 Million ≈ $43.76 Million |
-6.79pp |
| 2010-12-31 | 33.61% | €7.07 Million ≈ $8.27 Million |
€21.05 Million ≈ $24.61 Million |
+25.99pp |
| 2009-12-31 | 7.63% | €461.45K ≈ $539.49K |
€6.05 Million ≈ $7.08 Million |
-- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.